Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

tation, and 3 were EGFR wild-type.

-- All 6 patients with EGFR-activating mutations demonstrated clinical

benefit (5 PR, 1 SD).

-- XL647 is generally well tolerated in this patient population. The most

frequently reported adverse events assessed as being related to XL647

were diarrhea, rash, fatigue, and nausea, all of which were Grade 1 or

Grade 2 in severity.

"The data reported today demonstrate that XL647 has potential utility in patient populations with both mutated and wild-type EGFR," said Dr. Shirish Gadgeel of Karmanos Cancer Institute at Wayne State University. "Importantly, the data highlight that patients to date appear to have milder EGFR-related side-effects -- rash and diarrhea -- than previously described with other EGFR inhibitors while retaining potent anti-tumor activity with durable responses and stable disease. Although these are early results, they provide a compelling rationale for expediting the full development of XL647 in non-small cell lung cancer."

"These data suggest that XL647 has the potential for utility in patients with NSCLC who have an activating EGFR mutation and those with wild-type EGFRs. We believe these data support an aggressive clinical development strategy in first, second and third-line treatment as both a single agent and in combination with other therapies," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Moreover, new data from an ongoing phase 1 trial of XL647 suggest that daily dosing results in higher drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for the late-stage development of XL647."

The most frequently reported treatment-related adverse events (AEs) were Grade 1 and 2 diarrhea and fatigue, and Grade 1 nausea and rash. Six pat
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research Report ... "2014 Deep Research Report on Global and China ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... and China Acetic Acid Industry" is a professional ... and Global Acetic Acid Market. The ...
(Date:9/18/2014)... Texas Governor Rick Perry, Texas ... Health Science Center CEO Brett Giroir, M.D., and ... Human Services (HHS), State of Texas and biopharmaceutical ... vaccine manufacturing facility in Bryan, Texas, which when ... Texas A&M Biocorridor – a rapidly evolving hub ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Human Albumin Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The human albumin market analysis is provided ...
(Date:9/18/2014)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... in the Biotech Industry conference on Friday, September 26, ... Hotel & Conference Center in New York ... at www.meipharma.com . A replay will be available approximately ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... In eCTD Migration And Submissions Outsourcing And, Provides Insights Into ... ... And Europe, PHILADELPHIA and LONDON, July 17 The Scientific,business ... Regulatory Affairs Trends Survey. The survey attracted respondents,from across the globe ...
... Holdings, Inc. and its,operating subsidiary, US Oncology, Inc., ... August 7, 2008., A conference call and ... for the company,s bondholders following the distribution of ... Oncology,s management,team will discuss the financial results. Further ...
... TORONTO, July 16 /PRNewswire/ - Eugene Melnyk and ... see a number of incomplete or,inaccurate statements in ... "The hallmark of this proxy contest to date ... see the Board and management using the,same tactics," ...
Cached Biology Technology:The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 2The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 3
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a ... humans similar to that caused by Ebolavirus, has identified ... has the potential to lead to novel targets for ... research, reported in a paper published today in the ... at the Texas Biomedical Research Institute and their colleagues, ...
(Date:9/18/2014)... of researchers from McGill University and the Quebec ... polyethylene ,microbeads, Canadian Journal of Fisheries and ... from cosmetics, household cleansers, or industrial cleansers, to ... to their small size and buoyancy, they may ... are a global contaminant in the world,s oceans, ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Research milestone in CCHF virus could help identify new treatments 2Microplastic pollution discovered in St. Lawrence River sediments 2
... Troy, N.Y. The purification of drug components is ... particularly true of drugs that utilize proteins, which are ... Scientists within the Center for Biotechnology and Interdisciplinary Studies ... resonance (NMR) to understand and improve an important protein ...
... to anchor teeth back in the jaw using stem cells ... the first time by researchers at the University of Illinois ... advance in the battle against gum disease, a serious infection ... U.S. adults suffer from gum disease, according to the National ...
... recent human trials for a promising new class of ... without shutting down the immune system, some of the ... In response, an interdisciplinary team of Florida State ... genetic screening method that can identify the drug-resistant HCV ...
Cached Biology News:Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3Technique to reattach teeth using stem cells developed at UIC 2Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
RayBio Human Atherosclerosis Antibody Array 1.1 (4) with Accessory, detects 40 inflammatory factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Catch and Release® v2.0 Reversible Immunoprecipitation System...
... Peptide-Protein Conjugation, Quantities ... Complex Peptides/Peptidomimetics, Special amino ... Structures, Peptide labeling AMC, aldehyde, ... fitting your needs, Chromogenic/Flurogenic Substrates, ...
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
Biology Products: